These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25381974)

  • 1. Assays and strategies for immunogenicity assessment of biological agents.
    Nencini F; Pratesi S; Petroni G; Matucci A; Maggi E; Vultaggio A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S4-6. PubMed ID: 25381974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes.
    Shibata H; Nishimura K; Miyama C; Tada M; Suzuki T; Saito Y; Ishii-Watabe A
    J Immunol Methods; 2018 Jan; 452():73-77. PubMed ID: 28970009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.
    Liu Y; Reidler H; Pan J; Milunic D; Qin D; Chen D; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 64(3):238-45. PubMed ID: 21827863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.
    Vincent FB; Morand EF; Murphy K; Mackay F; Mariette X; Marcelli C
    Ann Rheum Dis; 2013 Feb; 72(2):165-78. PubMed ID: 23178294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
    Pan J; Small T; Qin D; Li S; Wang L; Chen D; Pauley C; Verch T; Kaplanski C; Bakhtiar R; Vallejo YR; Yin R
    J Pharmacol Toxicol Methods; 2011; 63(2):150-9. PubMed ID: 20868758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
    Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
    J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
    Cozzani E; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
    van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
    Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.
    Partridge MA; Purushothama S; Elango C; Lu Y
    J Immunol Res; 2016; 2016():6262383. PubMed ID: 27556048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a sensitive ELISA for the quantification of human tumour necrosis factor-alpha using 4 polyclonal antibodies.
    Grebenchtchikov N; van der Ven-Jongekrijg J; Pesman GJ; Geurts-Moespot A; van der Meer JW; Sweep FC
    Eur Cytokine Netw; 2005 Sep; 16(3):215-22. PubMed ID: 16266863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-PCR assays for immunogenicity testing.
    Spengler M; Adler M; Jonas A; Niemeyer CM
    Biochem Biophys Res Commun; 2009 Sep; 387(2):278-82. PubMed ID: 19577544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies.
    Zhong ZD; Jiang LL; Khandelwal P; Clarke AW; Bakhtiar R; Zou L
    AAPS J; 2020 Jan; 22(2):36. PubMed ID: 31997031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab.
    Mojtahed Poor S; Ulshöfer T; Gabriel LA; Henke M; Köhm M; Behrens F; Geisslinger G; Parnham MJ; Burkhardt H; Schiffmann S
    Clin Exp Immunol; 2019 May; 196(2):259-275. PubMed ID: 30656642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
    Mahil SK; Arkir Z; Richards G; Lewis CM; Barker JN; Smith CH
    Br J Dermatol; 2013 Aug; 169(2):306-13. PubMed ID: 23550925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology.
    Nechansky A
    J Pharm Biomed Anal; 2010 Jan; 51(1):252-4. PubMed ID: 19679421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
    Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.